Real-life effectiveness and safety of secukinumab in axial spondyloarthritis: a single-center study
Sign Up to like & getrecommendations! Published in 2022 at "Chinese Medical Journal"
DOI: 10.1097/cm9.0000000000002047
Abstract: Non-steroidal anti-inflammatory drugs (NSAIDs) are recommended as a first-line drug for axSpA patients. Failed to NSAIDs therapy, tumor necrosis factor (TNF)-a inhibitor (TNFi) was suggested in the treatment strategy of axSpA. But 30% of axSpA… read more here.
Keywords: real life; axial spondyloarthritis; life effectiveness; safety secukinumab ... See more keywords
Effectiveness and safety of secukinumab in patients with moderate‐severe psoriasis: A multicenter real‐life study
Sign Up to like & getrecommendations! Published in 2020 at "Dermatologic Therapy"
DOI: 10.1111/dth.14044
Abstract: This study assessed the effectiveness and safety of secukinumab in patients with moderate‐severe psoriasis vulgaris in a real‐world setting. A total of 120 patients (35.8% women; mean age 49.8 years) were enrolled. Mean PASI significantly decreased… read more here.
Keywords: effectiveness safety; study; safety secukinumab; secukinumab patients ... See more keywords
Efficacy and safety of secukinumab in treating moderate to severe plaque psoriasis in two real‐world Canadian dermatology clinics: a multicenter retrospective study
Sign Up to like & getrecommendations! Published in 2018 at "Journal of the European Academy of Dermatology and Venereology"
DOI: 10.1111/jdv.14468
Abstract: diomyopathy during therapy with dabrafenib and trametinib. When myocarditis was first reported during treatment with dabrafenib and trametinib, a warning was published by the European Medicine Agency and myocarditis added to the serious side-effects. Differential… read more here.
Keywords: dermatology; efficacy safety; secukinumab treating; moderate severe ... See more keywords